Neurology · DepressionRegulatory Approvalcommercialnear-term

FDA Grants AP Status for Aurobindo's Bupropion Hydrochloride

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/29/2026, 6:02:04 AM

Assessment confidence: 64% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's grant of ANDA status to Aurobindo for Bupropion Hydrochloride signifies a new competitive entrant in the antidepressant market. This development necessitates a reassessment of market strategies by existing players to maintain their market share and pricing integrity. Regulatory context from FDA (FDA AP — BUPROPION HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 24 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Aurobindo's entry on market share and pricing strategies for similar antidepressants. The strongest clinical anchor is Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN (ClinicalTrials.gov), sponsor/company relevance (novartis). In Neurology · Depression, 8 regulatory and 2 competitive items passed relevance filtering for Aurobindo Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approves Canagliflozin Application by Aurobindo Pharma (Humanexa Signals) — entity match (aurobindo pharma). Secondary pressure from FDA Grants Approval for Pitolisant Hydrochloride by Novitium Pharma. This approval allows Aurobindo to enter the market for Bupropion Hydrochloride, increasing competition against existing branded and generic products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — BUPROPION HYDROCHLORIDE (ORIG) (FDA). Entity match (aurobindo pharma); Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards, but does not introduce significant regulatory changes for the market.

Key Risks

Clinical risk from ClinicalTrials.gov (Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community) could weigh on Aurobindo Pharma through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Aurobindo's entry could lead to increased price competition and potential erosion of market share for existing products, impacting revenue streams.
Portfolio teams should assess the impact of Aurobindo's entry on market share and pricing strategies for similar antidepressants.

What Would Change This Assessment

This becomes more urgent if Monitor the launch timeline and market uptake of Aurobindo's Bupropion Hydrochloride.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — BUPROPION HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUPROPION HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUPROPION HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (bupropion hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ALFUZOSIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PITOLISANT HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Accelerated High-Dose tDCS for Depression
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Approves Canagliflozin Application by Aurobindo Pharma
Humanexa Signalshigh relevance
Entity match (aurobindo pharma)
FDA Grants Approval for Pitolisant Hydrochloride by Novitium Pharma
Humanexa Signalsmedium relevance
Moderate corpus alignment

Development and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Investigation of the pharmacodynamic material basis and mechanism of Gexia Zhuyu Decoction in the treatment of primary dysmenorrhea with qi stagnation and blood stasis based on Chinmedomics.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
An integrated approach combining transcriptomics, network pharmacology, and experimental validation are used to investigate the mechanism of Lonicerae Japonicae Flos and Forsythiae Fructus extracts ag
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Total organic acids from Cuscuta chinensis Lam. Modulate MDM2 to promote neurogenesis and alleviate depression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JMKX003002 in Chinese healthy participants: a randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, an
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma
Bupropion Hydrochloride

Commercial impact

medium

Aurobindo's entry could lead to increased price competition and potential erosion of market share for existing products, impacting revenue streams.

Regulatory impact

low

The approval indicates compliance with FDA standards, but does not introduce significant regulatory changes for the market.

What to watch

Monitor the launch timeline and market uptake of Aurobindo's Bupropion Hydrochloride.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.